Cold Spring Harbor Laboratory (CSHL) is ranked #1 on Innovation Impact’s Productivity Score among Pure Research/Health Care Institutions, as well as #1 for Patent Citations by the George W. Bush Presidential Center.
In their yearly report, “The Innovation Impact of U.S. Universities,” the Bush Center measures the innovations of American research institutions and highlights works from the top performers. CSHL was chosen as an institution that “illustrates the social benefits from cutting-edge research” through its basic research. The report highlights SPINRAZA®, the novel antisense oligonucleotide approved by the FDA for treating spinal muscular atrophy. It was developed by CSHL Professor Adrian Krainer.
CSHL was also ranked #1 in research output worldwide by the journal Nature in 2019, and has been named a Top Long Island Workplace two years in a row by Newsday.
This story originally appeared in the Winter 2020 edition of the Harbor Transcript magazine.
Written by: Sara Roncero-Menendez, Media Strategist | publicaffairs@cshl.edu | 516-367-8455